Ublituximab: a new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis

VO Boldrini, S Mader, T Kümpfel, E Meinl - Multiple Sclerosis and Related …, 2023 - Elsevier
Ublituximab, an intravenous glycoengineered chimeric anti-CD20 IgG1 monoclonal
antibody (mAb), is a new FDA-approved treatment for relapsing forms of Multiple Sclerosis …
被引用次数：5 相关文章

Ublituximab: A new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis

VO Boldrini, S Mader, T Kümpfel… - Multiple sclerosis and …, 2023 - pubmed.ncbi.nlm.nih.gov
Ublituximab, an intravenous glycoengineered chimeric anti-CD20 IgG1 monoclonal
antibody (mAb), is a new FDA-approved treatment for relapsing forms of Multiple Sclerosis …

Ublituximab: A new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis

VO Boldrini, S Mader, T Kümpfel… - Multiple Sclerosis and …, 2023 - msard-journal.com
Ublituximab, an intravenous glycoengineered chimeric anti-CD20 IgG1 monoclonal
antibody (mAb), is a new FDA-approved treatment for relapsing forms of Multiple Sclerosis …

Ublituximab: A new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis.

VO Boldrini, S Mader, T Kümpfel… - Multiple Sclerosis and …, 2023 - europepmc.org
Ublituximab, an intravenous glycoengineered chimeric anti-CD20 IgG1 monoclonal
antibody (mAb), is a new FDA-approved treatment for relapsing forms of Multiple Sclerosis …